Search Results

You are looking at 51 - 60 of 62 items for :

  • "peptide receptor radionuclide therapy (PRRT)" x
  • Refine by Access: All content x
Clear All
Free access

Anna Karpathakis, Martyn Caplin, and Christina Thirlwell

), chemotherapy, peptide receptor radionuclide therapy (PRRT), interferon-α (IFNα) and most recently the molecularly targeted agents sunitinib and everolimus. It is clear that marked differences in molecular pathogenesis are evident between NETs of different sites

Open access

Tobias Hofving, Yvonne Arvidsson, Bilal Almobarak, Linda Inge, Roswitha Pfragner, Marta Persson, Göran Stenman, Erik Kristiansson, Viktor Johanson, and Ola Nilsson

peptide receptor radionuclide therapy (PRRT) ( Kölby et al . 2005 , Bernhardt et al . 2007 , Forssell-Aronsson et al . 2013 , Dalmo et al . 2017 , Spetz et al . 2017 ). More recently, in 2009, three cell lines were established from a patient with

Free access

C R C Pieterman, S M Sadowski, J E Maxwell, M H G Katz, K E Lines, C M Heaphy, A Tirosh, J E Blau, N D Perrier, M A Lewis, J P Metzcar, D M Halperin, R V Thakker, and G D Valk

either minimal or unknown ( Raymond et al. 2011 , Yao et al. 2011 ). The most recent approved therapy for patients with GEP-NETs has been peptide receptor radionuclide therapy (PRRT) using 177 Lu-DOTATATE. The registration for the NETTER-1 trial

Free access

Tim J Takkenkamp, Mathilde Jalving, Frederik J H Hoogwater, and Annemiek M E Walenkamp

symptoms and reducing tumour growth are available and include somatostatin analogues, everolimus, sunitinib, peptide receptor radionuclide therapy (PRRT), interferon and chemotherapy. ( Pavel et al. 2012 , Phan et al. 2015 ). The tumour

Free access

Mairéad G McNamara, Jean-Yves Scoazec, and Thomas Walter

, and this may potentially explain the predominantly less than favourable results. Other options for combination with immunotherapy may include peptide receptor radionuclide therapy (PRRT) ( Kong & Hicks 2019 ). However, the use of PRRT in patients

Free access

Katharina Wang, Ina Schütze, Sebastian Gulde, Nicole Bechmann, Susan Richter, Jana Helm, Michael Lauseker, Julian Maurer, Astrid Reul, Gerald Spoettl, Barbara Klink, Doreen William, Thomas Knösel, Juliane Friemel, Michel Bihl, Achim Weber, Maria Fankhauser, Laura Schober, Diana Vetter, Martina Broglie Däppen, Christian G Ziegler, Martin Ullrich, Jens Pietzsch, Stefan R Bornstein, Christian Lottspeich, Matthias Kroiss, Martin Fassnacht, Vera Ursula Julia Wenter, Roland Ladurner, Constanze Hantel, Martin Reincke, Graeme Eisenhofer, Ashley B Grossman, Karel Pacak, Felix Beuschlein, Christoph J Auernhammer, Natalia S Pellegata, and Svenja Nölting

after two and three cycles of SSTR2-guided peptide receptor radionuclide therapy (PRRT) and F-18-SiFA-TATE PET/CT imaging of patient 34 prior to and after two cycles of PRRT. After two to three cycles of PRRT, Ga-DOTA-TOC PET/CT of patient 13 showed a

Free access

Maria P Yavropoulou, Marina Tsoli, Konstantinos Barkas, Gregory Kaltsas, and Ashley Grossman

symptomatic improvement and tumour control achieved in patients with atypical adenomas treated with peptide receptor radionuclide therapy (PRRT) ( Komor et al. 2014 ). However, prospective clinical trials are required to establish the efficacy and safety of

Open access

Susan Richter, Timothy J Garrett, Nicole Bechmann, Roderick J Clifton-Bligh, and Hans K Ghayee

have more slowly growing tumors, radiopharmaceutical agents, such as 131 I-metaiodobenzylguanidine targeting the norepinephrine transport system or peptide receptor radionuclide therapy (PRRT) taking advantage of somatostatin receptor type 2 expression

Free access

Anna Angelousi, Georgios K Dimitriadis, Georgios Zografos, Svenja Nölting, Gregory Kaltsas, and Ashley Grossman

Trimarchi F Cannavò S 2012 First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 8. 11In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment . Pituitary 15 57

Free access

Thomas Cuny, Wouter de Herder, Anne Barlier, and Leo J Hofland

radionuclide therapy (PRRT)  177Lu-DOTA0-Tyr3-Octreotate SSTR2 III (1): 177Lu-DOTA0-Tyr3-Octreotate + OCT 30 mg LAR/28 day vs (2): OCT 60 mg LAR/28 day ( NETTER trial) Nbib1578239 Unresectable and or metastatic well-differentiated midgut NETs